COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
To determine whether protective antibody levels increase after booster dosing with the
Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low
antibody levels after a prior first vaccination with any of the SARS-CoV2 vaccines that were
authorized for use in the USA. Researchers will also assess whether the booster dosing with
the Moderna COVID-19 vaccine is safe in patients with multiple myeloma, amyloidosis, or other
blood cancers.